Document details

Thrombotic microangiopathy mediated by complement in postpartum sequentially treated With plasmapheresis and eculizumab


Description

The complement-mediated thrombotic microangiopathy (TMA), also known as atypical hemolytic uremic syndrome (aHUS), is rare and potentially fatal, presenting as TMA and dysfunction/endothe - lial edema secondary to diffuse disruption of a fluid phase alternat - ing complementary pathways. We report a case of a young woman with postpartum anuric renal failure, TMA and normal levels of AD- AMTS13 with partial clinical improvement after plasmapheresis, in which treatment with eculizumab led to the complete reversal of the clinical manifestations. Our work includes a brief literature review on the diagnosis and management of TMA in puerperium. mor cells; small vessel vasculitis, autoimmune or infectious etiology; endothelial dysfunction, which may be mediated by complement or Shiga-like toxin [1]. The period of pregnancy and postpartum eventually com- plicates these conditions, by immunological changes (predis- posing the formation of autoantibodies), changes in clotting factors with decreased level of ADAMST13 enzyme, which cleaves factor multimers of von Willebrand, and own pregnan- cy (preeclampsia and clinical spectra). Most of the time, the differential diagnosis of these diseases is difficult, requiring a multidisciplinary approach for the best outcome of the patient. We report a case of a young postpartum, with hypertensive disorders of pregnancy, with TMA initially conducted as TTP, with partial response to plasmapheresis and complete response to eculizumab.

Document Type Journal article
Language English
facebook logo  linkedin logo  twitter logo 
mendeley logo

Related documents